

September 23 – 25, 2025 | Boston, MA

www.exosomebased-therapeutics.com

SAVE \$900 BY
REGISTERING
BEFORE
JUNE 13



7th Annual

Exosome-Based Therapeutic Development Summit

Accelerate Therapeutic Efficacy & Delivery Potential of Exosomes & EVs

Boosting Exosome & Extra-Cellular Vesicle Therapies & Delivery Carriers with Optimal Characterization, Improved Tropism & GMP-Grade Production for Regenerative & Precision Medicine

Expert Speakers Include:



Kuldeep Neote
Chief Executive
Officer
Diadem
Biotherapeutics



Sandra Mores
Chief Operating
Officer
EXO Biologics



Shelley Hartman
Chief Executive
Officer
Aegle Therapeutics



Steven Stice
Co-Founder & Chief
Scientific Officer
Aruna Bio



Timothy Moseley
Chief Scientific
Officer
Direct Biologics



Chris Paradise
Vice President
– Research &
Development
Rion

Proud to Partner With:

LONZA

DAICEL

nanofem

**UNCHAINED
LABS**

**Crealyve®
Biolabs**

+1 617 455 4188 @ info@hansonwade.com

www.exosomebased-therapeutics.com

hansonwade

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to the 7th Exosome-Based Therapeutic Development Summit!

7th Annual
Exosome-Based
Therapeutic Development Summit
September 23 – 25, 2025 | Boston, MA


With **Direct Biologics**, **Rion**, **Aegle Therapeutics**, **Aruna Bio**, **EXO Biologics**, and more now in the clinic, exosome and extra-cellular vesicle drug developers are realizing a newfound potential of these particles with improved safety and efficacy towards the first ever approval.

The **7th Exosome-Based Therapeutic Development Summit** returns to **Boston** as the world's only industry-dedicated biopharma forum to advance the R&D and manufacture of exosomes and extra-cellular vesicle-based therapeutics and delivery carriers for **precision** medicine, regenerative and cell therapy markets.

Uniting leaders from the **extracellular vesicle community** across biopharma and KOL academics, this year's 3 jam-packed days of content will uncover key bottlenecks, including:

 Breaking new ground with key **clinical data** from leading exosome specialists in the field to inform your strategies towards first approval

 Overcoming **targeted delivery** challenges with novel exosome delivery carriers transporting your cargo from RNA to DNA and beyond

 Diving deep into a brand-new **Exosome Characterization & Analytical Development Focus Day**, equipping you with innovative tools to measure, load, purify and scale GMP-compliant EV therapeutics

 Keeping up the momentum into 2025 by networking with key **partners and collaborators** to fuel the next generation of breakthroughs and R&D success

Join 80+ leading experts in exosomes and extracellular vesicles, with experts specializing in Exosome Biology, R&D, CMC, and Business Development. Take part in an unrivalled learning and networking opportunity to roadmap the therapeutic efficacy and delivery potential of exosomes and EVs towards commercialization and patients in need.

Brand New Companies for 2025:

AGS
Therapeutics

ARUNABIO

diadem
BIOTHERAPEUTICS

DIRECT  BIOLOGICS™

EV Therapeutics

turn.bio

VERSATOPE
Delivering Immunity

VESICURE
Therapeutics

Xosomix

EXORPHIA


Key Benefits Of Attending



Achieve the scale and manufacturing excellence of your exosome products with GMP compliance and batch-to-batch consistency for commercial viability with insights from **EXO Biologics**, **EverZom** & **NurExone Biologics**



Advance your pipelines toward the clinic with fresh data and experience from leading exosome & EV developers on the path towards the first therapeutic approval, with insights from **Direct Biologics**, **Rion**, **Aegle Therapeutics** & **Aruna Bio**



Harness translational strategies & therapeutic innovations with relevant translational model case-studies to reinvigorate your pipeline with insights from **EV Therapeutics**, **Diadem Biotherapeutics** & **Capricor Therapeutics**



Establish robust and standardized analytical and characterization methods to unlock size, surface markers, and exosome isolation techniques with insights from **VesiCURE Therapeutics**, **Loyola University Chicago** & **Exorpha**



Leverage exosomes & EVs as the delivery vehicle of choice for a variety of payloads with improved tropism, targeted delivery, and immunogenicity with insights from **ShiftBio** & **AGS Therapeutics**

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Expert Speakers

7th Annual
Exosome-Based
Therapeutic Development Summit
September 23 – 25, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Biopharma Leaders



Shelley Hartman
Chief Executive Officer
Aegle Therapeutics



Kristin Luther
Vice President of CMC &
Analytics
AGS Therapeutics



Steven Stice
Co-Founder & Chief
Scientific Officer
Aruna Bio



Mafalda Cacciottolo
Director of R&D
Capricor Therapeutics



Mickey Pentecost
Chief Scientific Officer
Diadem Biotherapeutics



Kuldeep Neote
Chief Executive Officer
Diadem Biotherapeutics



Timothy Moseley
Chief Scientific Officer
Direct Biologics



GianLuca Roma
Chief Executive Officer
EV Therapeutics



Doug Arm
Chief Operating Officer
EV Therapeutics



Nicolas Rousseau
Co-Founder & Chief
Operating Officer
EverZom



Sandra Mores
Chief Operating Officer
EXO Biologics



Kenichi Tamura
Head of CMC
Development
Exorpha



Ina Sarel
Head of CMC, Quality &
Regulatory
NurExone Biologic



Jahan Jowharchi
Chief Technical Operations
Rion



Chris Paradise
Vice President – Research
& Development
Rion



Inkyu Lee
R&D Senior Researcher
& Business Development
Senior Manager
Shiftbio



Hans Hofland
Senior Vice President of
Preclinical Development
Turn Biotechnologies



Bryan Allinson
Co-Founder & Chief
Executive Officer
Vanquish Bio



Jacki Kornbluth
Co-Founder & Chair for
Scientific Advisory Board
Vanquish Bio



Christopher Locher
Chief Executive Officer &
Co-Founder
Versatope



Xinjun He
Chief Scientific Officer &
Senior Vice President
VesiCURE Therapeutics



Xenia Sango
Chief Executive Officer &
Managing Director
VivaZome Therapeutics



Pranav Sharma
Founder & Chief Executive
Officer
Xosomix

Your Expert Speakers

7th Annual
Exosome-Based
Therapeutic Development Summit
September 23 – 25, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

KOL Academics



Steven Jay
Associate Professor
University of Maryland



Fatah Kashanchi
Professor of Virology
George Mason University



Phong Le
Professor of Microbiology ,
Immunology & and Cancer
Biology
**Loyola University
Chicago**



R. Kenneth Marcus
Professor of Chemistry
Clemson University

Solution Provider Experts



Clayton Deighan
North American Sales &
Applications Manager
NanoFCM



Joseph Barendt
Senior Director of
Business Development
Daicel Life Sciences

■ ■ The Exosome-Based Therapeutic Development Summit is one of the top tier in the field to exchange robust and clinical significant progress among biotech companies and researchers. Participants can potentially establish collaborations and social connections with similar visions in the field of exosome study ■ ■

Xinjun He, Chief Scientific Officer & Senior Vice President, VesiCURE Therapeutics

Pre-Conference Focus Day

Tuesday, September 23, 2025

 **Exosome-Based
Therapeutic Development Summit**
September 23 – 25, 2025 | Boston, MA

In the ever-evolving exosome field, the need for better standardization of analytical and characterization techniques and continues to be a major challenge, especially with candidates now moving towards the clinic.

The **Exosome Characterization & Analytical Development Focus Day** will deep dive into key insights and interactive discussions to support your **exosomes and EVs production, isolation, and identification** using the most established and robust techniques, using the most efficient tools, and ensuring high quality to advance progress from research to clinic effectively.



8.00 **Check-In & Morning Coffee**



GianLuca Roma
Chief Executive Officer
EV Therapeutics

8.50 **Chair's Opening Remarks**

Establishing Robust Analytical Methods to Better Characterize Exosomes with Improved Quantification & Precision



Fatah Kashanchi
Professor of Virology
George Mason University
New Data

9.00 **Case Study: Utilizing MSC-derived Extra-Cellular Vesicles to Repair Infected Cells**

- How to effectively purify MSC-derived extra-cellular vesicles
- Effectively characterizing cellular repair strategies
- Presenting *in vivo* and *in vitro* assays used for cellular repair



Steven Jay
Associate Professor
University of Maryland
New Data

9.30 **Leveraging Mechanical Regulation of Cell Phenotype for Scalable EV Production**

- How to design a mechanical environment for cell culture that's compatible with perfusion and/or flow-based bioreactor cultures for large-scale EV production
- Assessing effects of mechanical cell culture conditions on EV contents and activity
- Evaluating versatility of mechanical control of EV production and activity across multiple producer cell types



Kenichi Tamura
Head of CMC Development
Exorpha
New Data

10.00 **Cracking the Code: Predicting Exosome Pharmacology Through Physicochemical Insights**

- The critical need for predictive physicochemical testing in exosome drug development
- Key challenges in interpreting and correlating physicochemical data with pharmacological outcomes
- Our breakthrough case study: A successful prediction-to-performance story



10.30 **Morning Break & Networking**

Improving Purification Methods to Ensure Consistent & Homogenous Exosome Isolation for Therapeutic Use



R. Kenneth Marcus
Professor of Chemistry
Clemson University
New Data

11.00 **High Purity & Throughput Isolation of Exosomes via Capillary-Channeled Fiber Chromatography**

- The efficient isolation of high-purity populations of EVs is a limitation in fundamental biochemistry, clinical diagnostics, and vector production
- Hydrophobic interaction chromatography (HIC) on capillary-channeled polymer phases provides high purity and throughput with low capital costs
- Examples of isolation characteristics will be presented for matrices ranging from urine to plasma, cell cultures, and bovine milk



Xinjun He
Senior Vice President
VesiCURE Therapeutics
New Data

11.30 **Strengthening & Expanding siRNA Drug Capability via EV Delivery System**

- Building a leading chromatographic exosome purification capability for suspension and adherent cell cultures
- Developing a proprietary payload loading technologies for small interfering RNAs and active protein drugs.
- Therapeutically significant targets can be efficiently regulated in lung, skin and solid tumor disease models, paving the way for further clinical development

Pre-Conference Focus Day

Tuesday, September 23, 2025

12.00 **Panel Discussion: Harnessing Novel Technologies to Effectively Measure, Isolate & Characterise Exosome Cargoes**

- What novel technologies are coming onto the market to facilitate exosome characterization and advance the development of future therapeutics?
- What are the current challenges of isolating, purifying, and measuring exosomes effectively?
- How to effectively leverage novel imaging tools to successfully analyze exosome morphology and modifications?



GianLuca Roma
Chief Executive Officer
EV Therapeutics



R. Kenneth Marcus
Professor of Chemistry
Clemson University



Pranav Sharma
Founder & Chief Executive
Officer
Xosomix



1.00 **Lunch Break & Networking**

Demonstrating Effective Exosome Analytical & Quality Control Standards to Ensure Consistency & Reproducibility for Clinical Progress



Phong Le
Professor of
Microbiology &
Immunology and
Cancer Biology
Loyola University
Chicago
New Data

2.00 **Membrane Characterization of EVs from Genetic-Engineered Human Thymic Epithelial Cells: Implications in T Lymphopoiesis**

- Generate and characterize genetic-engineered human thymic epithelial cells expressing the Notch ligand DLL4 and the derived EVs/exosomes
- Analysis of EVs by multi-color flow cytometry and cluster analysis of EV heterogeneity
- Characterization of EV ligand-receptor interaction with hematopoietic stem cells (HSCs)

2.30 **Roundtable Discussion: Utilizing the Most Optimal Analytical Assays to Support Your Exosome Drug Product Release Strategies**

- Evaluating conventional and novel instruments to analyze exosomes across ELISA, acoustic Imaging, flow cytometry, and more to confidently select your technology
- Ensuring analytical methods are validating, qualifying, and reproducible to ensure safety and sterility of the exosome product
- One vs multiple potency assays – How to address complex mechanisms of action within the production phase



Ina Sarel
Head of CMC, Quality & Regulatory
NurExone Biologic



Kristin Luther
Vice President of CMC & Analytics
AGS Therapeutics

3.30 **Chair's Closing Remarks**

3.45 **End of Pre-Conference Focus Day**

■ I look forward to engaging with industry experts to drive innovation, regulatory alignment, and translational success in exosome therapeutics ■

Sandrine Mores, Chief Operating Officer, EXO Biologics

Conference Day One

Wednesday, September 24, 2025



7.30 **Check-In & Morning Coffee**



Jahan Jowharchi
Chief Technical
Operations
Rion

8.20 **Chair's Opening Remarks**

Boosting Exosome & Extra-Cellular Vesicle Innovation & Clinical Strategy Towards the First Therapeutic Approval



Chris Paradise
Vice President
– Research &
Development
Rion
New Data

8.30 **Clinical Application of Platelet-Derived Exosomes in Regenerative Medicine**

- Introduction to Rion's exosome-based drug product and MOA
- Current application of Rion's technology in clinical trials
- Forward-looking application of platelet-derived exosomes



Sandrine Mores
Chief Operation Officer
EXO Biologics
New Data

9.00 **Accelerating Exosome-Based Therapeutics: From Innovation to GMP-Ready Solution**

- Showcasing an update on EXO Biologics' clinical trials
- Presenting exosomes use as a safer alternative to viral drug delivery systems
- Ensuring the quality and compliance of your exosomes



Timothy Moseley
Chief Scientific Officer
Direct Biologics
New Data

9.30 **A Non-Conventional Pathway to Commercialize an EV Therapeutic**

- MSC secretome: Cell therapy without the cells
- Navigating direct biologics' pathway to phase III clinical trial
- Leveraging nature's mechanism of action for disease mitigation



10.00 **Morning Break & Speed Networking**

This session is your opportunity to get face-to-face with many of the brightest minds working in the exosome and extra-cellular vesicle therapy field, and establish meaningful business relationships to pursue for the rest of the conference

Advancing Clinical EV-Based Therapeutic Programs To Achieve Improved Safety & Mechanisms of Action in Patients



Steven Stice
Co-Founder & Chief
Scientific Officer
Aruna Bio
New Data

11.00 **Update on Cleared US FDA IND for Acute Ischemic Stroke Using Neural Stem Cell Derived EVs**

- AB126: A first-in-class EV Therapy for stroke and CNS diseases and designed to treat stroke patients with poor prognosis post-reperfusion: A high medical-need
- IND-cleared, with preliminary work underway for the first-in-human trial
- AB126 offers a novel, multi-target solution with a clear mechanisms or action that address inflammation, immune response and repair

11.30 **Session Reserved for: **Lonza****



Shelley Hartman
Chief Executive Officer
Aegle Therapeutics
New Data

12.00 **Clinical Advances in EV Therapies**

- Updating the field on Aegle's therapeutic clinical progress
- Highlighting where we go from here and overcoming key challenges

Conference Day One

Wednesday, September 24, 2025



12.30 Lunch Break & Networking

Envisioning the Success of Exosome & Extra-Cellular Vesicles Therapies Enabled by Robust Biopharma Partnerships & Scientific Collaboration

1.30 **Biopharma Leaders Panel Discussion: Unlocking the Next Wave of Safe & Efficient Exosome-Based Therapeutics Towards Clinical & Commercial Reality**

This is your chance to hear from pioneering executive leaders from the exosome and extra-cellular vesicle community who will discuss their strategies, challenges, and future perspectives for exosome technology and clinically relevant therapeutic applications.

- What are the future opportunities, promising targets, and applications on the horizon for exosomes to achieve clinical success?
- What can we learn from past experiences, principles, and guidelines to roadmap and accelerate the next 5 years of therapeutic development?
- What advice can you give this room of exosome experts to reduce risk, extend cash flow, and become an investable SME?



Jahan Jowharchi
Chief Technical
Operations
Rion



Nicolas Rousseau
Co-Founder &
Chief Operating
Officer
EverZom



Shelley Hartman
Chief Executive
Officer
**Aegle
Therapeutics**



Steven Stice
Co-Founder &
Chief Scientific
Officer
Aruna Bio



Timothy Moseley
Chief Scientific
Officer
**Direct
Biologics**



Joseph Barendt
Senior Director of
Business Development
Daicel Life Sciences

2.15 **Advances in EV Manufacturing: Case Studies of Fully Automated Exosome Isolation Systems**

- Process improvements combining chromatography and TFF
- Acceleration of clinical trial-scale process development
- Focus on improved purity while maintaining high yield



2.45 **Afternoon Break & Scientific Poster Session**

As the discovery and development of exosomes and extra-cellular vesicle-based therapeutics continues to advance, it is essential to collaborate and share knowledge to streamline the approval process. Share your latest findings and gain insight into the cutting-edge work of your peers and promote collaboration.

Supercharging EV-Based Carrier Delivery to Ensure Efficient Targeting & Efficacious Translation Towards the Clinic



Inkyu Lee
R&D Senior
Researcher & Business
Development Senior
Manager
Shiftbio
New Data

3.30 **AI-Driven Natural Drug Delivery Platform Technology for Enhanced In Vivo Delivery**

- Engineering Natural Nanoparticles (NNPs) using NNP Sorting Motif (NSM) for enhanced delivery
- Understanding the dynamics of engineered NNP surface proteins to recognize specific target cell types
- Elucidating the mechanism of NNP engineering through AI prediction



Clayton Deighan
North American Sales
& Applications Manager
NanoFCM

4.00 **Unlocking the Potential of Multicolor EV Characterization with Flow NanoAnalyzer**

- Reviewing the state of the art in multi-color labeling of biological nanoparticles like EVs and discuss important choices in instrumentation configuration, reagent selection, and experimental design
- The Flow Nanoanalyzer is a highly sensitive nano flow cytometry device designed specifically for the detection of nanoparticles and their associated dim fluorescent signals
- Discussing calibration for size and count of EVs, quantifications of fluorescent signals, and common experimental factors that can impact sensitivity

Conference Day One

Wednesday, September 24, 2025



Mafalda Cacciottolo
Director of Research & Development
Capricor Therapeutics
New Data

4.10

Can Extracellular Vesicles be Engineered for Muscle Delivery?

- Showcasing StealthX: Exosome-based platform for engineering of EVs
- Harnessing a muscle-targeting moiety to improve muscle delivery *in vitro* and *in vivo*
- Presenting possible applications of muscle-targeting EVs

4.40

Session Reserved for: **UNCHAINED LABS**



Kristin Luther
Vice President of CMC & Analytics
AGS Therapeutics
New Company

4.50

MEVs (Microalgae Extracellular Vesicles) – A Universal Delivery System for RNA Therapeutics, Vaccines & Gene Therapies

- Introducing MEVs and MEV technology
- Showcasing the uniqueness of MEVs compared with mammalian EVs
- Demonstrating MEV potential through data-driven case studies



Bryan Allinson
Co-Founder & Chief Executive Officer
Vanquish Bio

5.20

Chair's Closing Remarks

5.30

End of Conference Day One

■ ■ As an emerging therapeutic modality, it is essential that leaders in the exosome and EV space come together to exchange knowledge in an effort to accelerate translation of this technology into clinical practice ■ ■

Chris Paradise, Vice President – Research & Development, Rion

Conference Day Two

Thursday, September 25, 2025

 **Exosome-Based
Therapeutic Development Summit**
September 23 – 25, 2025 | Boston, MA

WELCOME



8.00 **Check-In & Morning Coffee**



Xenia Sango
Chief Executive Officer
& Managing Director
**VivaZome
Therapeutics**

8.50 **Chair's Opening Remarks**

Bridging the Clinical & Regulatory Gap for the Safe & Efficacious Development of Exosome-Based Therapeutics



Nicolas Rousseau
Co-Founder & Chief
Operating Officer
EverZom
New Data

9.00 **EverGel for Crohn Perianal Fistula: Exosomes Embedded in Hydrogel**

- Showcasing preclinical data in perianal fistula
- Highlighting quality control and regulatory challenges of a formulation with a hydrogel
- Outlining the regulatory preparation of a phase 1b/2a clinical trial in Crohn fistula



Ina Sarel
Head of CMC, Quality
& Regulatory
NurExone Biologic

9.30 **Roundtable Discussion: Harmonizing the Exosome & Extra-Cellular Vesicle Regulatory Landscape Towards Better Definitions, Practices & Guidelines for Therapeutic Success**

- What are the current gaps in knowledge of submissions, and what can we learn from current therapeutic progress in the clinic?
- How does the current regulatory guidance provide clarity on CMC changes for exosome-based therapeutics?
- How can the exosome biopharma industry and regulators continue to support each other to ensure global harmony and better therapeutics to patients faster?



10.00 **Morning Break & Networking**

Unlocking Exosome Therapeutics Manufacturing: Strategies for Stability, Scalability & Efficiency



Christopher Locher
Chief Executive Officer
& Co-Founder
Versatope
New Data

10.30 **Advancing Exosome-Based Therapies: From Bench to Bedside**

- Overcoming current manufacturing challenges
- Innovating novel delivery mechanisms for enhanced efficacy
- Showcasing clinical trial data and future directions



Ina Sarel
Head of CMC, Quality
& Regulatory
NurExone Biologic
New Data

11.00 **Advancing the Effective Production & Scale-Up of Exosomes Towards GMP-Grade Compliance**

- How to effectively scale exosomes for GMP-grade manufacturing from research to clinical
- Exploring strategies for minimizing batch-to-batch variations by optimizing sourcing processes, culture conditions, and ensuring uniformity in starting materials for efficient scale-up
- Ensuring quality EV isolation from a purified population of the right cell types and consistent supply using scalable processes

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Conference Day Two

Thursday, September 25, 2025

11.30 **Panel Discussion: Accelerating Scalable & Cost-Effective Extra-Cellular Vesicle Manufacturing for the Development of Therapeutics for Regenerative, Precision & CGT Therapies**

- Exploring cost-efficient exosome sources such as bodily fluids to reduce the high production costs associated with cell-derived exosomes
- Understanding the complexities involved in setting up pipelines for the purification and production of engineered exosomes to optimize cost considerations throughout the development process
- Delving into the factors contributing to the cost of engineered exosomes, including production methods and regulatory compliance, for strategic planning to manage expenses effectively



Kuldeep Neote
Chief Executive Officer
Diadem Biotherapeutics



Nicolas Rousseau
Co-Founder & Chief
Operating Officer
EverZom



Bryan Allinson
Co-Founder & Chief
Executive Officer
Vanquish Bio



Steven Jay
Associate Professor
University of Maryland



12.00 **Lunch Break & Networking**

Building an Investable Exosome Therapeutic Platform from Discovery R&D Towards Market Readiness



Xenia Sango
Chief Executive Officer
& Managing Director
VivaZome Therapeutics



1.00 **Roundtable Discussion: Delving into Market Conditions for Exosome/EV Therapy Development**

- Understanding how market conditions can influence investor interest and funding availability for exosome and EV therapy development
- Demonstrating clinical promise and addressing regulatory hurdles to mitigate investor concerns and maintain confidence in exosome and EV-based therapies
- Exploring the potential for new innovations in exosome and EV development to attract investment in exosome therapy development



Doug Arm
Chief Operating Officer
EV Therapeutics
New Data

1.30 **Strategic Development of a Native Extracellular Vesicle Platform Technology for Regenerative Medicine Therapeutic Applications**

- EV Therapeutics has broadened our portfolio to include a novel, native EV technology, synergistic with our modified EV therapeutic platform
- This platform technology has strong MOA data and is supported by positive clinical use data outside the USA
- Prioritizing this native EV technology enables EV Therapeutics to chart a more rapid path towards clinical trials and US regulatory approval



Pranav Sharma
Founder & Chief
Executive Officer
Xosomix
New Company

2.00 **Quantitative Protein Profiling of Extracellular Vesicles as a Platform for Therapeutics**

- AI-based Quantitative protein profiling of extracellular vesicles is a powerful platform that can revolutionize therapeutics and the efficacy of treatment
- Using EVs to develop a non-invasive diagnostic biomarker of endometriosis
- Development of EV-based therapy for Alzheimer's disease







2.30 **Afternoon Break & Networking**

Conference Day Two

Thursday, September 25, 2025

Innovating Exosome-Based Therapeutics to Tackle Rare & Oncology Indications Successfully

 Hans Hofland Senior Vice President of Preclinical Development Turn Biotechnologies New Data	3.00	Up in ARMMs - A Novel Delivery System for Multiple Payloads <ul style="list-style-type: none">• What are ARMMs• Gene Editing for Stargardt Disease• Other potential clinical uses for ARMMs
 Mickey Pentecost Chief Scientific Officer Diadem Biotherapeutics New Company	3.30	Exosome-Displayed Fusion Proteins Unlock TNF Receptor Superfamily Agonism for Cancer Immunotherapy <ul style="list-style-type: none">• Overcoming the challenge of TNFRSF agonism: limitations of traditional protein biologics• Engineering multivalent exosome display using a novel type II transmembrane anchor• Demonstrating superior agonist activity: <i>In vitro</i> and <i>in vivo</i> validation
 Jacki Kornbluth Co-Founder & Chair for Scientific Advisory Board Vanquish Bio New Company	4.00	Showcasing Natural Killer (NK) Cell Derived EVs as a New Treatment for Patients with Relapsed/Refractory Cancers <ul style="list-style-type: none">• Demonstrating NK EVs' strong and broad anti-tumor activity without harming healthy cells• Developing a new off-the-shelf biological product widely available to treat cancer patients who fail current treatments• Identifying a quantitative biomarker of NK EV activity
 Kuldeep Neote Chief Executive Officer Diadem Biotherapeutics	4.30	Chair's Closing Remarks
	4.40	End of 7th Exosome-Based Therapeutic Development Summit 2025

■ ■ This meeting is a chance to exchange ideas at the leading edge of exosome science. I value the opportunity to share insights from the lab, learn from others, challenge my assumptions and spark collaborations to drive real breakthroughs ■ ■

**Mickey Pentecost, Chief Scientific Officer,
Diadem Biotherapeutics**

Partner With Us

Your Global Platform to Elevate Your Company & Foster New Relationships Within the Rapidly Expanding Exosome & EV Field

As exosome and EV-based therapeutics advance across precision, regenerative and cell and gene industries, there is increasing demand for specialized outsourcing services to bring these medicines into clinical and commercial reality.

The **7th Exosome-Based Therapeutic Development Summit** provides the ultimate end-to-end platform to connect with leading stakeholders and showcase your innovative solutions to a global audience of **80+ EV experts**.

Biopharma companies globally seek expertise in:

Exosome & EV
CDMO

Exosome & EV CRO

Analytical &
Characterization

Purification &
Isolation

CryoEM & Imaging

Exosome & EV
Sourcing

MSC Production

GMP Manufacturing



Showcase Your Expertise:

Engage directly with decision-makers actively seeking advanced solutions in exosome and extracellular vesicle technologies by means of a presentation or exhibition booth.



Generate Valuable Leads:

Connect with industry leaders through our targeted networking opportunities, including speed networking sessions and informal gatherings designed to foster commercial partnerships.



Position Your Brand as a Leader:


With the exosome and extracellular vesicle field expanding rapidly, position yourself as a go-to industry expert for key stakeholders driving the future of exosome therapeutics.



Enhance Market Intelligence:

Gain invaluable insights into the current demands and future needs of biopharma and tailor your offerings to meet the evolving challenges faced by the exosome and EV communities.

SENIORITY OF ATTENDEES*



C-Level: 12.5%

President/VP: 15%

Director: 17.5%


Manager/Head: 20%

Scientist: 25%

Professor: 5%

Other: 5%

TYPES OF COMPANIES ATTENDING*



Drug
Developers

Academia
& Research
Institutes

Equipment
& Service
Providers

*Statistics taken from the 6th Exosome-Based Therapeutic Development Summit

GET INVOLVED



Trevor Mugabi
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com



Lonza - Expertise Partner

At Lonza Cell & Gene Technologies, we provide contract development and manufacturing services that enable pharma and biotech companies to realize life changing cell & gene therapies for their patients. From the building blocks of life to the delivery of your therapy to patients, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our unmatched expertise in process development, paired with our standardized, systematic approach to cGMP manufacturing have already demonstrated our ability and capabilities to successfully take cell & gene therapies to commercialization time and time again. We continuously invest to solve not just the current, but also the future challenges. Together, let's realize your life-changing therapy.

www.lonza.com



Daicel Life Sciences - Expertise Partner

Daicel Life Sciences offers advanced solutions for pharmaceuticals, including its latest Exosome Isolation System. This cutting-edge system processes up to 5 liters of feed into 20 ml in under 2 hours, combining chromatography and tangential flow filtration in a fully automated process. It ensures high-yield, high-purity exosome isolation with unmatched efficiency. Daicel's proprietary technology simplifies exosome isolation, making it a powerful tool for research and therapeutic applications.

www.daicel.com/lifesciences/en/



NanoFCM - Innovation Partner

NanoFCM designs advanced analytical instrumentation allowing the measurement of extracellular vesicles (EVs). The NanoAnalyzer platform offers a flexible, high throughput solution to for the single-particle, multiparameter characterisation of EVs using nano-flow cytometry. By measuring simultaneously physical size, concentration and phenotypic properties, the NanoAnalyzer assesses the presence of given biomarkers in EV samples in liquid biopsy applications. It is also used in the development of EV-based therapeutics, to confirm product purity and yield based on payload.

www.nanofcm.com



Unchained Labs – Innovation Partner

www.unchainedlabs.com



Creative Biolabs - Exhibition Partner

Creative Biolabs, founded by experienced scientists, specializes in premium exosome services and products. We offer comprehensive solutions for exosome sampling, analysis, manufacturing, and exosome-based applications. Our high-quality product supports all aspects of exosome research, including isolation, purification, qualification, antibodies, and engineering. Backed by cutting-edge technology and scientific expertise, we're committed to advancing your exosome research with reliable, innovative solutions.

www.creative-biolabs.com/exosome/

Ready to Register?

3 Easy Ways to Book



www.exosomebased-therapeutics.com/take-part/register/



Tel: +1 617 455 4188



Email: info@hansonwade.com



DISCOVER how exosome and EV platforms are realising their full potential to develop and manufacture effectively for therapeutic applications in precision, regenerative and cell & gene therapies



UNLOCK your R&D strategy with a biopharma leaders outlook and fresh data insights to accelerate your exosome delivery and development to clinical success



NETWORK with 80+ exosome peers from industry experts to solution providers to forge long-lasting collaborations and partnerships

Drug Developer Pricing*	Register by Friday, June 13 & Save \$900	On the Door Price
Conference + Focus Day	\$3,297 (Save \$900)	\$4,197
Conference Only	\$2,499 (Save \$500)	\$2,999

Academic Pricing**	Register by Friday, June 13 & Save \$900	On the Door Price
Conference + Focus Day	\$2,697 (Save \$900)	\$3,597
Conference Only	\$2,099 (Save \$500)	\$2,599

Service & Solution Provider Pricing	Register by Friday, June 13 & Save \$900	On the Door Price
Conference + Focus Day	\$4,197 (Save \$900)	\$5,097
Conference Only	\$3,199 (Save \$500)	\$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & research rate you must be full time academic. Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending


Team Discounts***

- 10% Discount – 2 Attendees
- 15% Discount – 3 Attendees
- 20% Discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

The Colonnade
120 Huntington Ave, Boston, MA 02116, United States
www.colonnadehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom



+1 617 455 4188 @ info@hansonwade.com

www.exosomebased-therapeutics.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE